1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
60BE51694BA87D7D5652578CB00404C99
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/0BE51694BA87D7D5652578CB00404C99!OpenDocument
18
19OpenDocument
2052.91.221.160
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Market Entry: Metabolic and Cardiovascular Diseases

Complimentary Excerpt: Pitfalls to Avoid for a Strong Metabolic Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls

DB Image

Excerpt in Cart

ID: MD-253


Features:

Metrics, Graphics


Pages/Slides: 4


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

To download this excerpt, click "
Download Free Excerpt".


To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5141 "Pitfalls to Avoid for a Strong Metabolic Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal, and Regulatory Pitfalls."


Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Health Care; Chemical; Manufacturing; Consumer Products; Diagnostic; Media


Companies Profiled:
Abbott Laboratories; Amgen; Actelion; AstraZeneca; GlaxoSmithKline; Bristol-Myers Squibb; Roche; Lilly; Novartis; Merck; Genentech; MedImmune; Bayer; Cephalon; Inc.; Teva Neuroscience; Novo Nordisk; Amylin; Laboratorios Deramtologicos Darier; IDS Canada; UCB Pharma; Quintiles; Ther-Rx; ProCaps Laboratories; Baxter Healthcare; Synapse biomedical; Talecris; Eisai; Shire; Takeda Pharmaceuticals


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.